Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F R Appelbaum

Showing results (471-480 of 490) with videos related to

Pageof 49
Sort By:
Leukemia|August 30, 2002
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)R A Larson, M Boogaerts, E Estey, et al.
Bone Marrow Transplantation|November 18, 1998
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancerL A Holmberg, T Demirer, S Rowley, et al.
Bone Marrow Transplantation|June 1, 1997
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancerW I Bensinger, K S Schiffman, L Holmberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myelomaW I Bensinger, S D Rowley, T Demirer, et al.
Blood|May 15, 1997
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulinR Storb, W Leisenring, C Anasetti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 14, 1997
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?R Storb, W Leisenring, C Anasetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseE L Sievers, R A Larson, E A Stadtmauer, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Leukemia Research|June 27, 2000
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617T R Chauncey, C Rankin, J E Anderson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 1996
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recoveryK M Sullivan, J Storek, K J Kopecky, et al.
Pageof 49

Showing results (471-480 of 490) with videos related to

Sort By:
Pageof 49
Leukemia|August 30, 2002
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)R A Larson, M Boogaerts, E Estey, et al.
Bone Marrow Transplantation|November 18, 1998
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancerL A Holmberg, T Demirer, S Rowley, et al.
Bone Marrow Transplantation|June 1, 1997
High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancerW I Bensinger, K S Schiffman, L Holmberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myelomaW I Bensinger, S D Rowley, T Demirer, et al.
Blood|May 15, 1997
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulinR Storb, W Leisenring, C Anasetti, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 14, 1997
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?R Storb, W Leisenring, C Anasetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseE L Sievers, R A Larson, E A Stadtmauer, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Leukemia Research|June 27, 2000
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617T R Chauncey, C Rankin, J E Anderson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 1996
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recoveryK M Sullivan, J Storek, K J Kopecky, et al.
Pageof 49